Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose aerosolized Moli1901 in adolescents and adults with cystic fibrosis
2005-004344-30Phase 2Completed
- Sponsor
- AOP Health
- Start
- Sep 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of Lancovutide in cystic fibrosis (CF) (2 cohorts), sponsored by AOP Health. Primary endpoints: Safety and tolerability and Pulmonary function changes. Started Sep 2005; status: completed.
02
Drugs
Lancovutide
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2005-004344-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004344-30.